

Diansheng Zhong

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/709949/diansheng-zhong-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

27
papers

140
citations

6
h-index

9
g-index

57
ext. papers

215
ext. citations

2.2
avg, IF

2.92
L-index

#	Paper	IF	Citations
27	Case Report: Dramatic Response to Crizotinib in a Patient With Non-Small Cell Lung Cancer Positive for a Novel Fusion.. <i>Frontiers in Oncology</i> , 2022 , 12, 804330	5.3	0
26	Identification of a DNA damage repair gene-related signature for lung squamous cell carcinoma prognosis.. <i>Thoracic Cancer</i> , 2022 ,	3.2	1
25	Targeting the EMT transcription factor Snail overcomes resistance to osimertinib in EGFR-mutant non-small cell lung cancer. <i>Thoracic Cancer</i> , 2021 , 12, 1708-1715	3.2	6
24	Safety and efficacy of administering reduced doses of pegylated recombinant human granulocyte-colony stimulating factors in patients treated with cisplatin and etoposide for small cell carcinoma: A retrospective study. <i>Thoracic Cancer</i> , 2021 , 12, 1154-1161	3.2	2
23	Difficult differential diagnosis of bladder pedicled masses about metastasis from non-small cell lung cancer: A case report. <i>Cancer Biology and Therapy</i> , 2021 , 22, 106-111	4.6	1
22	The role of brain metastases in patients with pulmonary adenocarcinoma: a retrospective study.. <i>Annals of Palliative Medicine</i> , 2021 , 10, 12262-12272	1.7	0
21	Routine-Dose and High-Dose Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 21-L858R Mutation: the Randomized, Phase II, INCREASE Trial. <i>Clinical Cancer Research</i> , 2020 , 26, 3162-3171	12.9	8
20	Molecular mechanism of acquired drug resistance in the EGFR-TKI resistant cell line HCC827-TR. <i>Thoracic Cancer</i> , 2020 , 11, 1129-1138	3.2	3
19	Study of anlotinib combined with icotinib as the first-line treatment in non-small cell lung cancer (NSCLC) patients harboring activating EGFR mutations (ALTER-L004).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 9573-9573	2.2	2
18	Effect of Betulin on Inflammatory Biomarkers and Oxidative Status of Ova-Induced Murine Asthma. <i>Journal of Environmental Pathology, Toxicology and Oncology</i> , 2020 , 39, 213-224	2.1	1
17	EGFR exon 19-deletion aberrantly regulate ERCC1 expression that may partly impaired DNA damage repair ability in non-small cell lung cancer. <i>Thoracic Cancer</i> , 2020 , 11, 277-285	3.2	2
16	CDK4/6 inhibitor palbociclib overcomes acquired resistance to third-generation EGFR inhibitor osimertinib in non-small cell lung cancer (NSCLC). <i>Thoracic Cancer</i> , 2020 , 11, 2389-2397	3.2	11
15	Fosaprepitant versus aprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy: a multicenter, randomized, double-blind, double-simulated, positive-controlled phase III trial. <i>Annals of Translational Medicine</i> , 2020 , 8, 234	3.2	2
14	An open label, multicenter, noninterventional study of apatinib in advanced gastric cancer patients (AHEAD-G202). <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920905424	5.4	6
13	Retrospective study of the efficacy and toxicity of lobaplatin-etoposide chemotherapy in small cell lung cancer. <i>Thoracic Cancer</i> , 2019 , 10, 226-233	3.2	2
12	High kinesin family member 18A expression correlates with poor prognosis in primary lung adenocarcinoma. <i>Thoracic Cancer</i> , 2019 , 10, 1103-1110	3.2	5
11	Glutamine- β -cyclodextrin for targeted doxorubicin delivery to triple-negative breast cancer tumors via the transporter ASCT2. <i>Journal of Materials Chemistry B</i> , 2019 , 7, 5363-5375	7.3	11

10	Oral fluoropyrimidine versus intravenous 5-fluorouracil for the treatment of advanced gastric and colorectal cancer: Meta-analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018 , 33, 209-225	4.5	13
9	Inhibition of IGF1R enhances 2-deoxyglucose in the treatment of non-small cell lung cancer. <i>Lung Cancer</i> , 2018 , 123, 36-43	5.9	6
8	Apatinib in patients with adenocarcinoma of stomach or gastroesophageal junction: A prospective, multicenter, non-interventional study (Ahead-G202).. <i>Journal of Clinical Oncology</i> , 2018 , 36, e16047-e16047	3.2	0
7	Liver kinase B1/adenosine monophosphate-activated protein kinase signaling axis induces p21/WAF1 expression in a p53-dependent manner. <i>Oncology Letters</i> , 2018 , 16, 1291-1297	2.6	5
6	Comparing the adverse effects of platinum in combination with etoposide or irinotecan in previously untreated small-cell lung cancer patients with extensive disease: A network meta-analyses. <i>Thoracic Cancer</i> , 2017 , 8, 170-180	3.2	1
5	Concurrent epidermal growth factor receptor T790M secondary mutation and epithelial-mesenchymal transition in a lung adenocarcinoma patient with EGFR-TKI drug resistance. <i>Thoracic Cancer</i> , 2017 , 8, 693-697	3.2	6
4	2-Deoxyglucose Suppresses ERK Phosphorylation in LKB1 and Ras Wild-Type Non-Small Cell Lung Cancer Cells. <i>PLoS ONE</i> , 2016 , 11, e0168793	3.7	18
3	EGFR gene-mutation status correlated with therapeutic decision making in lung adenocarcinoma. <i>OncoTargets and Therapy</i> , 2015 , 8, 3017-20	4.4	8
2	Lonafarnib is a potential inhibitor for neovascularization. <i>PLoS ONE</i> , 2015 , 10, e0122830	3.7	4
1	Significant decrease of ADP release rate underlies the potent activity of dimethylenastron to inhibit mitotic kinesin Eg5 and cancer cell proliferation. <i>Biochemical and Biophysical Research Communications</i> , 2014 , 447, 465-70	3.4	3